title: Mission critical: mobilization of essential animal models for Ebola, Nipah, and Machupo virus infections.
abstract: The reports for Ebola virus Zaire (EBOV), Nipah virus, and Machupo virus (MACV) pathogenesis, in this issue of Veterinary Pathology, are timely considering recent events, both nationally and internationally. EBOV, Nipah virus, and MACV cause highly lethal infections for which no Food and Drug Administration (FDA) licensed vaccines or therapies exist. Not only are there concerns that these agents could be used by those with malicious intent, but shifts in ecological distribution of viral reservoirs due to climate change or globalization could lead to more frequent infections within remote regions than previously seen as well as outbreaks in more populous areas. The current EBOV epidemic shows no sign of abating across 3 West African nations (as of October 2014), including densely populated areas, far outpacing infection rates of previous outbreaks. A limited number of cases have also arisen in the United States and Europe. With few treatment options for these deadly viruses, development of animal models reflective of human disease is paramount to combat these diseases. As an example of this potential, a new treatment compound, ZMapp, that had demonstrated efficacy against EBOV infection in nonhuman primates (NHPs) received an emergency compassionate use exception from the FDA for the treatment of 2 American medical workers infected with EBOV, and they are currently virus free and recovering.
authors.affiliation: Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA Elizabeth.Zumbrun@uscmed.sc.edu.
authors.forename: E E
authors.initials: EE
authors.lastname: Zumbrun
mesh_terms: D000818:Animals; D006477:Arenaviruses, New World / Q000187:drug effects / Q000502:physiology*; D057231:Climate Change; D057176:Compassionate Use Trials; D004195:Disease Models, Animal; D004196:Disease Outbreaks; D029043:Ebolavirus / Q000187:drug effects / Q000502:physiology*; D058872:Epidemics; D005060:Europe / Q000453:epidemiology; D006478:Hemorrhagic Fever, American / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D019142:Hemorrhagic Fever, Ebola / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D045464:Henipavirus Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D038622:Internationality; D045405:Nipah Virus / Q000187:drug effects / Q000502:physiology*; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
keywords: digestive tract; disease process; guinea pig; hamster; infectious; laboratory animals; liver; nervous tissue; primate; respiratory; species; viral